How Does Lactulose Work in Hepatic Encephalopathy?

Lactulose lowers blood ammonia, the toxic compound at the heart of hepatic encephalopathy, by acidifying the contents of the colon so that ammonia gets trapped there and expelled in stool instead of being absorbed back into the bloodstream. It is a synthetic sugar that human enzymes cannot digest, so it passes intact into the large intestine where bacteria ferment it into organic acids. That fermentation sets off a cascade of effects that together reduce the ammonia load reaching the brain. The mechanism sounds simple, but the details reveal why lactulose has remained a first-line treatment for decades and why getting the dose right matters so much.

Why Ammonia Is the Problem

In a healthy body, the liver converts ammonia into urea, which the kidneys then excrete. Ammonia is generated constantly, mostly by gut bacteria breaking down proteins and by normal cellular metabolism. When the liver is severely damaged, whether from cirrhosis, acute liver failure, or another cause, it can no longer clear ammonia efficiently. Blood levels climb, and because ammonia crosses the blood-brain barrier readily, brain levels follow.

Inside the brain, astrocytes are the only cells equipped to detoxify ammonia. They do this by converting it into glutamine. But glutamine is osmotically active, meaning it draws water into the cell. When ammonia floods in faster than astrocytes can cope, they swell. That swelling is the primary driver of the cerebral edema seen in hepatic encephalopathy, and in severe cases it can raise intracranial pressure to dangerous levels.¹² The clinical result ranges from subtle cognitive slowing (difficulty concentrating, poor reaction times) to confusion, disorientation, and coma. Reducing ammonia is therefore the central therapeutic goal, and that is where lactulose comes in.

What Lactulose Actually Is

Lactulose is a synthetic disaccharide made of galactose and fructose linked together in a way that does not occur in nature.³ Because human digestive enzymes in the stomach and small intestine cannot break that bond, the sugar arrives intact in the colon. There, resident bacteria happily ferment it, producing short-chain organic acids such as lactic acid and acetic acid. This fermentation is the engine behind every downstream effect lactulose has on ammonia.

The Three Ways Lactulose Reduces Ammonia

Researchers have identified at least three overlapping mechanisms, and there is still some debate about which contributes the most.

Colonic Acidification and Ion Trapping

When bacteria ferment lactulose, the organic acids they produce drop the pH inside the colon. This is the mechanism most commonly cited in textbooks, and the chemistry is straightforward. Ammonia exists in two forms: a neutral gas (NH₃) that can pass through cell membranes, and a charged ion (NH₄⁺) that cannot. At normal colonic pH, a meaningful fraction of ammonia is in the uncharged form and can diffuse from the gut lumen into the blood. When the pH drops below about 6.2, the balance shifts decisively toward the charged form. Ammonia that is already in the colon gets trapped as ammonium ions, and ammonia in the blood actually diffuses back into the acidic gut lumen, where it too becomes trapped. The trapped ammonium is then flushed out with stool.⁴ In healthy volunteers given lactulose, total ammonia and nitrogen excretion in feces goes up, supporting the idea that the gut is genuinely pulling ammonia out of circulation.⁴

Faster Transit and Less Time for Ammonia Production

Lactulose is also an osmotic laxative. By drawing water into the colon, it speeds up transit time and produces loose stools. Some researchers have argued that this cathartic effect matters as much as the pH change: when stool moves through the colon faster, bacteria have less time to break down proteins and generate ammonia. The faster transit also physically flushes out ammonia-producing bacteria themselves.⁵ This is one reason clinicians titrate the dose to achieve two to three soft bowel movements per day: too few means the ammonia-lowering effect is insufficient; too many means dehydration and electrolyte problems, which can themselves trigger an encephalopathy episode.

Shifting the Gut Microbiome

The organic acids produced by lactulose fermentation do not just change pH; they also alter which bacteria thrive. Acid-tolerant species such as Lactobacillus and Bifidobacterium tend to expand, while ammonia-producing, urease-containing bacteria decline. A multicenter randomized trial in patients with minimal hepatic encephalopathy found significant shifts in several major bacterial groups, including Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria, among patients who responded to lactulose compared with those who did not.⁶ Quantitative modeling work has also suggested that a major action of lactulose may be boosting ammonia uptake by bacteria in the small bowel, not just the colon, adding another layer to the story.⁷

In practice, all three mechanisms likely work together. The relative contribution of each probably depends on the individual patient’s gut flora, diet, colonic transit time, and the severity of liver disease. This helps explain why clinical response to lactulose varies from person to person.

Evidence in Acute Hepatic Encephalopathy

When someone with cirrhosis arrives at a hospital in a confused or obtunded state, lactulose is typically one of the first things administered. In a double-blind trial comparing lactulose and lactitol (a similar sugar alcohol) for acute episodes, roughly two-thirds of patients in both groups returned to a clinically normal state by the end of treatment.⁸ That is a meaningful response rate, though it also means a third of patients need additional or different interventions.

More recently, polyethylene glycol electrolyte solution, the same bowel-prep drink used before colonoscopies, has been tested against lactulose in the acute hospital setting. In a randomized trial, over 90% of patients given polyethylene glycol improved within 24 hours compared with about half of those on standard lactulose therapy, and the median time to resolution of encephalopathy was one day versus two days.⁹ A systematic review and meta-analysis later confirmed that polyethylene glycol improved clinical scores more rapidly than lactulose within the first 24 hours, though the two treatments did not differ significantly in ammonia reduction.¹⁰ That finding is interesting because it suggests the rapid bowel cleanout from polyethylene glycol may physically clear ammonia-laden gut contents faster, even without the pH-lowering trick that lactulose uses.¹¹ Still, lactulose remains the standard in most guidelines partly because the long-term data on polyethylene glycol for maintenance therapy is thin.

Preventing Recurrence

Lactulose is not just a treatment for acute episodes; it is one of the main tools for stopping them from coming back. In a randomized controlled trial, patients with cirrhosis who had already recovered from one bout of hepatic encephalopathy were assigned to either lactulose or placebo. Over a median follow-up of 14 months, about 20% of the lactulose group developed a recurrence compared with nearly 47% of those on placebo.¹² That is a substantial reduction in recurrence, and it is why most hepatologists keep patients on lactulose indefinitely after a first episode.

A separate study looked at what predicted recurrence among patients prescribed lactulose. The standout finding was that adherence mattered enormously: every patient who stayed free of recurrence was taking their lactulose as directed, while among those who relapsed, only about two-thirds had been adherent. On multivariate analysis, non-adherence carried an odds ratio of about 3.3 for recurrence, making it the strongest modifiable predictor.¹³ Some recurrences among adherent patients were triggered by infections, gastrointestinal bleeding, or low sodium levels, all of which can spike ammonia independently of what lactulose is doing.

Side Effects and the Adherence Problem

The single biggest obstacle to lactulose therapy is that many patients hate taking it. The drug is extremely sweet, has a thick syrupy consistency, and reliably causes bloating, gas, and diarrhea. These are not incidental complaints; they are often the reason people stop taking it. A review of long-term management noted that lactulose’s adverse effects include severe diarrhea, low potassium, low sodium, bloating, flatulence, nausea, and vomiting, and that roughly 29% of recurrences were linked to patients stopping lactulose because of gastrointestinal side effects.¹⁴

The irony is that overdoing it with lactulose can itself precipitate an episode. Too many bowel movements lead to dehydration and electrolyte disturbances, both of which are known triggers for hepatic encephalopathy. In the adherence study, about 8% of recurrences were attributed to lactulose-associated dehydration.¹³ This creates a narrow therapeutic window: enough lactulose to keep ammonia down, not so much that you dehydrate and make things worse. Patients and caregivers are usually told to aim for two to three soft stools daily and to adjust the dose up or down based on what their bowels are doing.

Minimal Hepatic Encephalopathy

Not all hepatic encephalopathy is obvious. Many patients with cirrhosis have what clinicians call minimal (or covert) hepatic encephalopathy: they look and sound fine in ordinary conversation but perform poorly on neuropsychological tests measuring attention, reaction time, and working memory. This matters in daily life because it affects driving ability, work performance, and fall risk.

Lactulose has been shown to help even in this subtler form. A controlled trial found that after three months of treatment, the average number of abnormal neuropsychological tests dropped substantially in the lactulose group while staying flat in the untreated group, and patients’ self-reported quality of life improved along with their test scores.¹⁵ Those quality-of-life gains are reinforced by data showing that about three-quarters of patients whose minimal encephalopathy resolved on lactulose reported significant improvements in daily functioning.¹⁶ Another trial comparing lactulose, rifaximin, and placebo for minimal encephalopathy found reversal rates of about 71% with lactulose, 70% with rifaximin, and only 11% with placebo.¹⁷

Despite this evidence, screening for minimal hepatic encephalopathy is inconsistent. Many clinicians do not routinely test for it because the diagnostic tools are specialized and time-consuming. That means a significant number of patients with cirrhosis are walking around with treatable cognitive impairment that nobody has identified.

Adding Rifaximin to Lactulose

Rifaximin is a gut-selective antibiotic that barely gets absorbed into the bloodstream, so it acts almost entirely inside the intestine. It reduces ammonia production by killing ammonia-generating bacteria, approaching the problem from a different angle than lactulose. Using the two together has become common practice, and the data supports it.

A systematic review and meta-analysis pooling data from multiple trials found that the combination of rifaximin and lactulose improved clinical outcomes by about 30% compared with lactulose alone and cut the risk of death by over 40%.¹⁸ A separate meta-analysis reported similar findings and added that you would need to treat about five patients with the combination (instead of lactulose alone) for one additional patient to achieve a clinical response, and about nine to prevent one death. Hospital stays were also shorter with the combination, and adverse events were no worse.¹⁹

Population-level data reinforces these findings. In a large cohort study, patients receiving lactulose alone had markedly fewer hospital days per year than untreated patients, and those on the lactulose-rifaximin combination had the fewest hospital days of any group.²⁰ In practice, most guidelines now recommend adding rifaximin after a second episode of overt hepatic encephalopathy in patients already on lactulose.

Rectal Administration

When a patient is too confused or comatose to swallow, or when vomiting makes oral dosing impossible, lactulose can be given as a retention enema. A diluted solution is instilled into the rectum and held for a period to allow colonic acidification. In one randomized study, patients who received rectal lactulose alongside oral therapy moved to lighter stages of encephalopathy much faster: by 48 hours, about 62% of the enema group had reached a mild grade compared with only 15% of those on oral therapy alone.²¹ This route bypasses the upper GI tract entirely, delivering the drug straight to the colon where it needs to work, and it remains useful in intensive-care settings where patients cannot take anything by mouth.

Lactitol as an Alternative

Lactitol is a sugar alcohol that works on the same principle as lactulose: it is not absorbed in the small intestine, reaches the colon intact, and gets fermented into acids that lower colonic pH. Head-to-head trials have consistently shown the two drugs to be equally effective. A meta-analysis pooling the available comparison trials found no statistical difference in improvement rates or encephalopathy scores between lactitol and lactulose.²² Where the two do differ is tolerability. Lactulose causes significantly more flatulence, and many patients find its intense sweetness nauseating.²³ Lactitol comes as a powder that can be mixed into water, has a milder taste, and tends to produce less gas. Despite these advantages, lactitol is less widely available in many countries, and lactulose remains the default in most clinical settings largely through historical inertia and familiarity.

Beyond Ammonia

There are hints that lactulose may do more than just manage ammonia levels. Cirrhosis is associated with increased intestinal permeability, sometimes called “leaky gut,” which allows bacterial products like endotoxin to cross from the gut into the bloodstream and drive systemic inflammation. Small studies have found that lactulose treatment lowers both serum endotoxin and markers of gut-lining damage in patients with cirrhosis.²⁴ Whether this anti-endotoxin effect translates into meaningful clinical benefits beyond what ammonia reduction already provides is still unclear. But it fits with a broader understanding that hepatic encephalopathy is not purely an ammonia problem; inflammation, oxidative stress, and changes in neurotransmitter signaling all play supporting roles. Lactulose, by reshaping the gut environment, may be nudging several of these factors at once, which could partly explain why it works as well as it does even though its ammonia-lowering ability is modest in absolute terms.